Latest News for: Pharmaceutical sources

Edit

‘Port Charles’ Star David Gail’s Cause of Death Revealed

Tyler Morning Telegraph 24 Feb 2024
“He struggled to stop taking pharmaceuticals and did before turning toward a more Eastern pain management including acupuncture and natural medicines,” she said ... from uncontrolled sources.”.
Edit

David Gail's cause of death revealed

Tyler Morning Telegraph 24 Feb 2024
He struggled to stop taking pharmaceuticals and did before turning toward a more Eastern pain management including acupuncture and natural medicines ... part in self-medicating from uncontrolled sources.
Edit

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free ...

The Huntsville Item 24 Feb 2024
ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd ... In 2023, Humira was one of the highest grossing pharmaceutical products in the world, with sales in the U.S ... Sources ... Teva Pharmaceutical Industries Ltd ... SOURCE.
Edit

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Enid News & Eagle 23 Feb 2024
Amylyx Pharmaceuticals, Inc ... Arsenault of non-qualified stock option awards to purchase up to 101,400 shares of the Company’s common stock and 67,600 RSUs under the Amylyx Pharmaceuticals, Inc ... About Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc.
Edit

NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq

Pharmiweb 23 Feb 2024
ZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd ... About NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd ... For more information, please visit www.nlspharma.com ... NLS Pharmaceutics Ltd. +1 239.682.8500 ... SOURCE. NLS Pharmaceutics AG ... .
Edit

Global Propylene Glycol Industry Report 2023: Forecast and Analysis 2012-2023 and 2023-2027 - ResearchAndMarkets.com

The Eagle-Tribune 23 Feb 2024
Propylene glycol, a colorless and odorless liquid, finds extensive use in sectors ranging from food and beverage, pharmaceuticals, cosmetics, to industrial applications like antifreeze and de-icing solutions ... SOURCE.
Edit

AbCellera to Present at Upcoming Investor Conferences in March

Maryville Daily Forum 23 Feb 2024
AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development ... SOURCE.
Edit

Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference

The Eagle-Tribune 23 Feb 2024
Ironwood Pharmaceuticals, Inc ... About Ironwood Pharmaceuticals. Ironwood Pharmaceuticals (Nasdaq ... Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland ... SOURCE. Ironwood Pharmaceuticals, Inc.
Edit

AbCellera Announces Resignation of Board Member

The Joplin Globe 23 Feb 2024
AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development ... BIOTECHNOLOGY PHARMACEUTICAL HEALTH. SOURCE.
Edit

Global Cephalosporin Drug Market Forecast to Reach USD 21.9 Billion by 2029: Exceptional Growth in ...

The Eagle-Tribune 23 Feb 2024
Hoffmann-La Roche AGEli Lilly and CompanyAbbott LaboratoriesMerck & Co., Inc.NovartisSanofiPfizerTeva Pharmaceutical ... ResearchAndMarkets.com is the world's leading source for international market research reports and market data ... SOURCE.
Edit

Global Biopharma R&D Boasts Increased Funding, Productivity and Product Launches in 2023, says IQVIA Institute Report

The Eagle-Tribune 23 Feb 2024
Large pharmaceutical companies have shifted country utilization over the last decade by reprioritizing and rationalizing country selection for trials ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20240223378641/en/.
Edit

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase ...

The Eagle-Tribune 23 Feb 2024
Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20240223959968/en/.
Edit

Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

The Eagle-Tribune 23 Feb 2024
Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S ... About Venatorx Pharmaceuticals ... View source version on businesswire.com.https.//www.businesswire.com/news/home/20240223169844/en/ ... SOURCE.
Edit

Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients ...

The Eagle-Tribune 23 Feb 2024
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN ... Dr ... The presented Iomab-B Phase 3 SIERRA trial results and highlights include. ... TP53 Positive ... About Actinium Pharmaceuticals, Inc ... SOURCE Actinium Pharmaceuticals, Inc ... .
Edit

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

The Eagle-Tribune 23 Feb 2024
This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors.
×